ESBATech's Antibody Fragment ESBA105 Enters Phase IIa in Uveitis Study
New Clinical Advisory Board Established to Provide Industry Leadership and Ophthalmology Experience
ESBATech AG announced the initiation of a Phase IIa study in patients with acute anterior uveitis. This study is designed to evaluate the safety, tolerability, and clinical activity of topically applied ESBA105 in uveitis patients. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, a major mediator of inflammation. The Phase IIa trial is being conducted at several uveitis centers in Germany.
The primary objectives of this study are to assess the local tolerability and safety of topical ESBA105, as well as to evaluate the clinical activity of patients suffering from an attack of acute, unilateral anterior uveitis. With this Phase IIa study in uveitis and recently announced Phase Ib/IIa study in patients undergoing cataract surgery, the company continues to advance a pipeline of novel, antibody fragment therapeutics for local delivery in ocular diseases to ensure safe and convenient patient therapy.
ESBA105 is also being studied in other therapeutic indications such as osteoarthritis (OA). Earlier this year, ESBATech initiated a Phase I/IIa clinical study to explore clinical activity of ESBA105 in osteoarthritis of the knee.
Other news from the department research and development
